Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added α-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury

Am J Clin Nutr. 2019 Apr 1;109(4):1038-1050. doi: 10.1093/ajcn/nqy370.

Abstract

Background: Fish oil (FO) intravenous lipid emulsions (ILEs) are used as a monotherapy to treat parenteral nutrition (PN)-associated liver disease and provide essential fatty acids (EFAs) needed to sustain growth and prevent EFA deficiency (EFAD). Studies have suggested that medium-chain triglycerides (MCTs) and α-tocopherol have anti-inflammatory properties.

Objective: The purpose of this study was to test whether FO-ILEs containing MCTs and/or additional α-tocopherol decrease the inflammatory response to an endotoxin challenge compared with FO-ILE alone and preserve the ability to prevent PN-induced liver injury in mice.

Methods: A murine model of PN-induced hepatosteatosis was used to compare the effects of ILEs formulated in the laboratory containing varying ratios of FO and MCTs, and subsequently FO- and 50:50 FO:MCT-ILE plus 500 mg/L α-tocopherol (FO + AT and 50:50 + AT, respectively). C57BL/6 mice receiving unpurified diet (UPD), PN-equivalent diet (PN) + saline, and PN + soybean oil (SO)-ILE served as controls. After 19 d, mice received an intraperitoneal saline or endotoxin challenge 4 h before being killed. Serum and livers were harvested for histologic analysis, fatty acid profiling, and measurement of systemic inflammatory markers (tumor necrosis factor-α, interleukin-6).

Results: All ILEs were well tolerated and prevented biochemical EFAD. Livers of mice that received saline and SO developed steatosis. Mice that received 30:70 FO:MCT developed mild hepatosteatosis. All other FO-containing ILEs preserved normal hepatic architecture. Mice that received FO- or SO-ILE had significantly elevated systemic inflammatory markers after endotoxin challenge compared with UPD-fed controls, whereas 50:50 FO:MCT, 30:70 FO:MCT, FO + AT, and 50:50 + AT groups had significantly lower inflammatory markers similar to those seen in UPD-fed controls.

Conclusions: Mixed FO/MCT and the addition of α-tocopherol to FO improved the inflammatory response to endotoxin challenge compared with FO-ILE alone while still preventing PN-induced liver injury and EFAD in mice. There was no synergistic relation between α-tocopherol and MCTs.

Keywords: fish oil; hepatosteatosis; injectable lipid emulsions; intestinal failure–associated liver disease; intravenous fat emulsions; medium-chain triglycerides; parenteral nutrition; parenteral nutrition–associated liver disease; α-tocopherol.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / chemistry
  • Disease Models, Animal
  • Fat Emulsions, Intravenous / administration & dosage*
  • Fat Emulsions, Intravenous / chemistry
  • Fish Oils / administration & dosage*
  • Fish Oils / chemistry
  • Humans
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Liver Diseases / etiology
  • Liver Diseases / genetics
  • Liver Diseases / immunology
  • Liver Diseases / prevention & control*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Parenteral Nutrition / adverse effects*
  • Triglycerides / administration & dosage*
  • Triglycerides / chemistry*
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / immunology
  • alpha-Tocopherol / administration & dosage*

Substances

  • Anti-Inflammatory Agents
  • Fat Emulsions, Intravenous
  • Fish Oils
  • Interleukin-6
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • alpha-Tocopherol